What targeted therapies are available for Thyroid Cancer

Targeted Therapies for Thyroid Cancer

Targeted therapies have become an important treatment option for thyroid cancer patients, especially those with advanced or radioactive iodine-refractory disease (cancer that no longer responds to radioactive iodine treatment). Let me walk you through the main options and how doctors think about using them.

How Doctors Approach Targeted Therapy

According to the NCCN Guidelines for Thyroid Carcinoma, targeted therapies are considered when:

• The tumor cannot be surgically removed
• The cancer doesn't respond to radioactive iodine therapy
• The cancer is not suitable for radiation or other local treatments
• The disease is showing clinical progression (getting worse) over 6-12 months

The key principle is that these drugs work by targeting specific genetic mutations or pathways that cancer cells depend on to grow.

---

Main Categories of Targeted Therapies

1. Kinase Inhibitors (Multi-Targeted)

These are drugs that block multiple growth pathways in cancer cells. According to NCCN Guidelines, several kinase inhibitors are used for thyroid cancer:

Lenvatinib (preferred option)

• FDA-approved for radioactive iodine-refractory differentiated thyroid cancer
• Response rate: approximately 65% of patients show tumor shrinkage
• Progression-free survival: about 18.3 months (compared to 3.6 months with placebo)
• Works by blocking blood vessel growth and other cancer growth signals

Sorafenib

• Also FDA-approved for radioactive iodine-refractory disease
• Response rate: approximately 12% show tumor shrinkage
• Can be used as an alternative to lenvatinib

Other kinase inhibitors that may be considered:

• Sunitinib
• Axitinib
• Cabozantinib (also used for medullary thyroid cancer)
• Pazopanib
• Vandetanib (preferred for medullary thyroid cancer)

2. BRAF Mutation-Targeted Therapy

If your cancer has a BRAF V600E mutation (a specific genetic change), targeted therapy becomes particularly relevant:

Dabrafenib/Trametinib combination

• Targets the BRAF mutation directly
• Can also help restore radioactive iodine sensitivity in some patients
• In clinical trials, 95.2% of patients showed restored iodine uptake
• 38% showed partial tumor response, with 52% showing stable disease

3. RET Mutation-Targeted Therapies

For cancers with RET gene mutations (more common in medullary thyroid cancer):

Selpercatinib and Pralsetinib

• Preferred options for RET mutation-positive disease
• Specifically designed to block RET pathway signaling

4. TRK Inhibitors

For rare cases with TRK gene fusions:

• Larotrectinib
• Entrectinib
• Repotrectinib

5. ALK Inhibitors

For papillary thyroid carcinoma with ALK gene fusion:

• Data suggests ALK inhibitors may be effective
• Still being studied in clinical trials

6. Immunotherapy (PD-1 Inhibitors)

Pembrolizumab (anti-PD-1 antibody)

• Helps the immune system recognize and attack cancer cells
• Being studied for advanced thyroid cancer
• May be particularly useful for certain genetic profiles

---

How Well Do These Work?

According to NCCN Guidelines, clinical trials show that kinase inhibitors generally provide:

• Clinical benefit (partial response or stable disease) in 50-60% of patients
• Duration of benefit: typically 12-24 months
• Side effect management: Most side effects can be managed with dose adjustments or medication changes

---

Important Side Effects to Know About

The NCCN Guidelines note that kinase inhibitors can cause serious side effects, including:

• Bleeding
• High blood pressure (hypertension)
• Stroke
• Liver toxicity
• Hand-foot skin reactions
• Fatigue

However, most side effects are reversible if the drug is stopped or the dose is reduced.

---

Genetic Testing: The First Step

Before starting targeted therapy, the NCCN Guidelines recommend testing your tumor for potentially actionable mutations:

• BRAF mutations
• RET mutations
• TRK fusions
• ALK fusions
• Microsatellite instability (MSI)
• Tumor mutational burden (TMB)

This testing helps your doctor identify which targeted therapy is most likely to work for YOUR specific cancer.

---

Questions to Ask Your Oncologist

1. Has my tumor been tested for genetic mutations (BRAF, RET, TRK, ALK)? If not, should it be?

2. Based on my specific mutation status and disease stage, which targeted therapy do you recommend?

3. What is the expected response rate and duration of benefit for the therapy you're recommending?

4. What are the most common side effects I should watch for, and how will we manage them?

5. Are there clinical trials available that might be appropriate for my situation?

6. How will we monitor whether the therapy is working? (imaging, tumor markers like thyroglobulin)

7. If this therapy stops working, what are my next options?

8. How often will I need appointments and imaging scans while on this therapy?

---

Key Takeaway

Targeted therapies represent a significant advancement in thyroid cancer treatment, particularly for advanced disease. The choice of therapy depends on your specific genetic mutations, disease stage, and overall health. According to the NCCN Guidelines for Thyroid Carcinoma, the trend is moving toward personalized medicine—matching the right drug to your cancer's specific genetic profile.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.